Skip to content

Clinical Efficacy Evaluation of Qingzhixiaoyan Decoction in the Treatment of the Hyperlipidemia Caused by Aromatase Inhibitor for the Postmenopausal Breast Cancer

Clinical Efficacy Evaluation of Qingzhixiaoyan Decoction in the Treatment of the Hyperlipidemia Caused by Aromatase Inhibitor for the Postmenopausal Breast Cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100047070
Enrollment
Unknown
Registered
2021-06-07
Start date
2021-06-01
Completion date
Unknown
Last updated
2022-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

Sponsors

Shuguang Hospital Affiliated to Shanghai University of traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. All patients after surgical treatment were meet the pathological diagnostic criteria of breast cancer; The positive expression of estrogen receptor (ER) and / or progesterone receptor (PR) was confirmed by immunohistochemistry; 2. Postmenopausal women; 3. KPS score >= 60; 4. The diagnosis of hyperlipidemia was in accordance with the relevant standards of "Chinese guidelines for the prevention and treatment of dyslipidemia for adults"; 5. The diagnosis of TCM was in accordance with the standard of "liver depression and phlegm coagulation syndrome" in the "diagnostic efficacy standard of TCM"; 6. The patients had good compliance, could understand the situation of this study and signed the informed consent, which was approved by the hospital ethics committee.

Exclusion criteria

Exclusion criteria: 1. Severe acute and chronic diseases, such as acute myocardial infarction, acute pancreatitis, stroke, heart failure, or familial dyslipidemia; 2. Allergic to statins or known drugs; 3. Language, mental retardation or other reasons can not cooperate with the study and follow-up; 4. Other lipid-lowering drugs were taken in recent 4 weeks; 5. Patients with other malignant tumors, severe hepatic or renal insufficiency; 6. participated in other clinical trials in recent 3 months; 7. Received chemoradiotherapy within 1 month.

Design outcomes

Primary

MeasureTime frame
blood lipids;Chinese Medicine syndrome score;

Secondary

MeasureTime frame
tumor markers;Cassette function status scoring standard;Breast Cancer Quality of Life Scale;

Countries

China

Contacts

Public ContactFeng Danqing

Shuguang Hospital Affiliated with Shanghai University of traditional Chinese Medicine

appledaisy12@hotmail.com+86 13917246586

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026